Multicenter phase II trial of Genexol-PM, a Cremophor-free, polymeric micelle formulation of paclitaxel, in patients with metastatic breast cancer
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
Genexol-PM is a novel Cremophor EL-free polymeric micelle formulation of paclitaxel. This single arm, multicenter phase II study was designed to evaluate the efficacy and safety of Genexol-PM in patients with histologically confirmed metastatic breast cancer (MBC). Forty-one women received Genexol-PM by intravenous infusion at 300 mg/m2 over 3 h every 3 weeks without premedication until disease progression or intolerability. A total of 331 chemotherapy cycles were administered, with a median of 8 cycles per patient (range, 1-16). Overall response rate was 58.5% (95% CI: 43.5-72.3) with 5 complete responses and 19 partial responses. Thirty-seven patients who received Genexol-PM as a first-line therapy for their metastatic disease showed a response rate of 59.5% (95% CI: 43.5-73.7), and two responses were reported in four patients treated in the second-line setting for their metastatic disease. The median time to progression (TTP) for all patients was 9.0 months (range, 1.0-17.0+ months). Grade 3 non-hematologic toxicities included sensory peripheral neuropathy (51.2%), and myalgia (2.4%). Eight patients (19.5%) experienced hypersensitivity reactions, with grade 3 in two patients. Hematologic toxicities were grade 3 and 4 neutropenia (51.2 and 17.1%, respectively), and grade 1 and 2 thrombocytopenia (22.0%). Notably, no febrile neutropenia was observed. Genexol-PM appears a promising new paclitaxel in view of significant efficacies. Further trials with different dosing schedules, durations of delivery, or in combination with other drugs are warranted.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Since then, many polymeric micelle formulations have reached clinical trials in several countries [9, 10, 300].”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [9]
In the citing paper
“Another phase II study in South Korea reported the clinical benefit of Genexol® PM in patients with metastatic breast cancer [9]. Forty-one patients were enrolled in the study and administered with a Genexol® PM infusion (300 mg/m2) every 3 weeks. The overall response rate was 58.5%, which is superior to that of Abraxane® (47.6%) and Taxol® (21–54%).”
From Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval. (2020) · cites this paper as [9]
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181 · cited 1×
“TTP and survival were summarized by using Kaplan–Meier methods [15].”
MethodNonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660 · cited 2×
“Measurable disease was assessed by imaging using the RECIST criteria [ 12 ].”
MethodGradishar, W. J., Tjulandin, S., Davidson, N., Shaw, H., Desai, N., Bhar, P., Hawkins, M., & O'Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,153 · cited 12×
“In this study the combined incidence of grade 3 and 4 neutropenia was 68.3%, while this incidence in a phase II trial of ABI-007 was 50.8%.”
BackgroundMethodInfluentialGelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655 · cited 2×
“venous administration of paclitaxel requires the use of solubilizing agents such as Cremophor EL (CrEL) [2], which compromise the therapeutic value of paclitaxel in many aspects.”
BackgroundDesai, N., Trieu, V., Yao, Z., Louie, L., Ci, S., Yang, A., Tao, C., De, T., Beals, B., Dykes, D., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,175 · cited 1×
“litaxel concentrations achieved by ABI-007, an albuminbound paclitaxel, are due to albumin binding to the endothelial gp60 receptor with transcytosis of bound paclitaxel through the caveolar transport system [27, 29].”
BackgroundKim, T.-Y., Kim, D.-W., Chung, J.-Y., Shin, S. G., Kim, S.-C., Heo, D. S., Kim, N. K., & Bang, Y.-J. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0655 · Cited by 821 · cited 4×
“The polymeric micelle formulation is composed of hundreds of low molecular weight, nontoxic, and biodegradable amphiphilic diblock copolymers which include monomethoxy poly(ethylene glycol)-blockpoly(D,L-lactide), and has a great potential in terms of water solubility, in vivo stability, and the nanoscopic size (a dia…”
BackgroundInfluentialSelf-citationIn vivo evaluation of polymeric micellar paclitaxel formulation: toxicity and efficacy
Kim, S. C., Kim, D. W., Shim, Y. H., Bang, J. S., Oh, H. S., Kim, S. W., & Seo, M. H. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(01)00275-9 · Cited by 734 · cited 3×
“The polymeric micelle formulation is composed of hundreds of low molecular weight, nontoxic, and biodegradable amphiphilic diblock copolymers which include monomethoxy poly(ethylene glycol)-blockpoly(D,L-lactide), and has a great potential in terms of water solubility, in vivo stability, and the nanoscopic size (a dia…”
BackgroundSelf-citationSledge, G. W., Neuberg, D., Bernardo, P., Ingle, J. N., Martino, S., Rowinsky, E. K., & Wood, W. C. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.013 · Cited by 707 · cited 1×
“In another large randomized study conducted by the ECOG, first-line paclitaxel in comparison with doxorubicin and the combination of doxorubicin and paclitaxel showed response rate of 34% [20].”
BackgroundEisenhauer, E. A., ten Bokkel Huinink, W. W., Swenerton, K. D., Gianni, L., Myles, J., van der Burg, M. E., Kerr, I., Vermorken, J. B., Buser, K., & Colombo, N. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.12.2654 · Cited by 626
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Peripheral Neuropathy Induced by Microtubule-Stabilizing Agents
Lee, J. J., & Swain, S. M. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0543 · Cited by 472 · cited 1×
“ment cycle, the schedule of treatment, and the duration of infusion [6, 32].”
BackgroundNabholtz, J. M., Gelmon, K., Bontenbal, M., Spielmann, M., Catimel, G., Conte, P., Klaassen, U., Namer, M., Bonneterre, J., Fumoleau, P., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.6.1858 · Cited by 380
Paridaens, R., Biganzoli, L., Bruning, P., Klijn, J. G. M., Gamucci, T., Houston, S., Coleman, R., Schachter, J., Van Vreckem, A., Sylvester, R., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.724 · Cited by 364 · cited 1×
“son with doxorubicin as a first-line therapy [19].”
BackgroundNovel formulations of taxanes: a review. Old wine in a new bottle?
Hennenfent, K. L., & Govindan, R. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj100 · Cited by 345 · cited 1×
“Given the drawbacks resulting from the use of CrEL as a solubilizer, new CrEL-free formulations of paclitaxel are of great interest for development in clinical use [9].”
BackgroundLiggins, R. T., & Burt, H. M. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00016-9 · Cited by 286 · cited 1×
“Genexol-PM and other CrEL-free paclitaxels invariably showed higher intratumoral drug concentrations than conventional CrEL-based paclitaxel regardless of the vehicles [11, 30, 31].”
BackgroundWiner, E. P., Berry, D. A., Woolf, S., Duggan, D., Kornblith, A., Harris, L. N., Michaelson, R. A., Kirshner, J. A., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270 · cited 3×
“Seven to 33% of patients receiving CrEL-based paclitaxel reportedly experienced grade 3 or 4 sensory PN depending on the administered doses [18].”
BackgroundInfluentialIbrahim, N. K., Samuels, B., Page, R., Doval, D., Patel, K. M., Rao, S. C., Nair, M. K., Bhar, P., Desai, N., & Hortobagyi, G. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.013 · Cited by 267 · cited 12×
“In this study the combined incidence of grade 3 and 4 neutropenia was 68.3%, while this incidence in a phase II trial of ABI-007 was 50.8%.”
BackgroundMethodInfluentialTumor targeting by covalent conjugation of a natural fatty acid to paclitaxel.
Bradley, M. O., Webb, N. L., Anthony, F. H., Devanesan, P. D., Witman, P. A., Hemamalini, S., Chander, M. C., Baker, S. D., He, L., Horwitz, S. B., et al. (2001) · PubMed · Cited by 211
Bishop, J. F., Dewar, J., Toner, G. C., Smith, J., Tattersall, M. H. N., Olver, I. N., Ackland, S., Kennedy, I., Goldstein, D., Gurney, H., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2355 · Cited by 209
Seidman, A. D., Reichman, B. S., Crown, J. P., Yao, T. J., Currie, V, Hakes, T. B., Hudis, C. A., Gilewski, T. A., Baselga, J., & Forsythe, P. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1152 · Cited by 205
Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes
Mielke, S., Sparreboom, A., & Mross, K. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.06.030 · Cited by 186 · cited 2×
“ment cycle, the schedule of treatment, and the duration of infusion [6, 32].”
BackgroundSmith, R. E., Brown, A. M., Mamounas, E. P., Anderson, S., Lembersky, B. C., Atkins, J. H., Shibata, H. R., Báez, L., DeFusco, P. A., Davila, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3403 · Cited by 151
Gianni, L., Munzone, E., Capri, G., Villani, F., Spreafico, C., Tarenzi, E., Fulfaro, F., Caraceni, A. T., Martini, C., Laffranchi, A., et al. (1995) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/87.15.1169 · Cited by 144
Kloover, J. S., Bakker, M. A. D., Gelderblom, H., & Meerbeeck, J. P. V. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601303 · Cited by 138
Designs for Group Sequential Phase II Clinical Trials
Chang, M. N., Therneau, T. M., Wieand, H. S., & Cha, S. S. (1987) · Biometrics · doi:10.2307/2531540 · Cited by 135 · cited 1×
“The study used a two-stage group sequential design [14], with 90% power to detect a response rate of 50% and <5% chance of continuing the trial if the response was <30% (Fig.”
MethodSuccessful parenteral desensitization to paclitaxel
Essayan, D. M., Kagey‐Sobotka, A., Colarusso, P., Lichtenstein, L. M., Ozols, R. F., & King, E. D. (1996) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(96)70281-6 · Cited by 109 · cited 1×
“When histamine release was observed with paclitaxel while no histamine was released by CrEL alone, paclitaxel was assumed to be the probable cause of hypersensitivity [33].”
BackgroundPhthalate Esters and Their Effect on the Liver
Ganning, A. E., Brunk, U. T., & Dallner, G. (1984) · Hepatology · doi:10.1002/hep.1840040331 · Cited by 107 · cited 1×
“As DEHP is suspected to be a hepatotoxin, carcinogen, teratogen, and mutagen [7, 8], special infusion sets must be used clinically when administering CrEL-based paclitaxel to circumvent this leaching problem.”
BackgroundHill, S. S., Shaw, B. R., & Wu, A. H. B. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(00)00411-3 · Cited by 99 · cited 1×
“As DEHP is suspected to be a hepatotoxin, carcinogen, teratogen, and mutagen [7, 8], special infusion sets must be used clinically when administering CrEL-based paclitaxel to circumvent this leaching problem.”
BackgroundThe RING-H2 protein RNF11 is overexpressed in breast cancer and is a target of Smurf2 E3 ligase
Subramaniam, V., Li, H., Wong, M., Kitching, A. R., Attisano, L., Wrana, J. L., Zubovits, J. T., Burger, A. M., & Seth, A. K. (2003) · British Journal of Cancer · doi:10.1038/sj.bjc.6601301 · Cited by 95
A phase II study of paclitaxel in advanced breast cancer resistant to anthracyclines
Fountzilas, G., Athanassiades, A., Giannakakis, T., Bafaloukos, D. I., Karakousis, K., Dombros, N., Kosmidis, P., & Skarlos, D. V. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00398-3 · Cited by 53
Kim, S. C., Yoon, H. J., Lee, J. W., Yu, J.-W., Park, E., & Chi, S. (2005) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2005.01.011 · Cited by 41 · cited 1×
“Genexol-PM also resulted in significantly lower leaching of a plasticizer from infusion sets compared to CrEL-based paclitaxel [16].”
Self-citationCsako, G., McGriff, N. J., Rotman-Pikielny, P., Sarlis, N. J., & Pucino, F. (2001) · Annals of Pharmacotherapy · doi:10.1345/aph.1a031 · Cited by 40
Use and abuse of taxanes in the management of metastatic breast cancer
Bernard-Marty, C., Cardoso, F., & Piccart, M. J. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(03)00538-0 · Cited by 24 · cited 10×
“Conventional CrEL-based paclitaxel showed response rates of 21–54% as a first-line therapy in patients with MBC [18–22].”
BackgroundInfluential
Research works printed but not linked: 1
- Kintzel PE (2001) Prophylaxis for paclitaxel hypersensitivity reactions. Ann Pharmacother 35:1114–1117 · doi:10.1345/aph.10287
Cited by
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Biodegradable polymeric nanoparticles based drug delivery systems
Kumari, A., Yadav, S. K., & Yadav, S. C. (2010) · Colloids and Surfaces B: Biointerfaces · doi:10.1016/j.colsurfb.2009.09.001 · Cited by 3,724
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Strategies in the design of nanoparticles for therapeutic applications
Petros, R. A., & DeSimone, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd2591 · Cited by 3,651
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Metadata
- Authors
- Lee, K. S., Chung, H. C., Im, S. A., Park, Y. H., Kim, C. S., Kim, S.-B., Rha, S. Y., Lee, M. Y., & Ro, J.
- Affiliations
- Korean Cancer Study Group (KR)
- Yonsei University (KR)
- Seoul National University (KR)
- Inha University (KR)
- Asan Medical Center (KR)
- Samyang Holdings (South Korea) (KR)
- Corresponding author
- Ro, Jungsil
- ORCID
- Venue
- Breast Cancer Research and Treatment
- Published
- 2007-05-03
- Volume
- 108
- Issue
- 2
- Pages
- 241-250
- ISSN
- 0167-6806 (ISSN-L)
- 1573-7217
- OpenAlex
- W2091796668
- Cited by
- 541
- References
- 34
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 29 · 2023: 22 · 2022: 29 · 2021: 35 · 2020: 37 · 2019: 28 · 2018: 36 · 2017: 31 · 2016: 43 · 2015: 40 · 2014: 45 · 2013: 35 · 2012: 28
- FWCI
- 8.10
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by-nc-nd
- www.springer.com/tdm (tdm)
- Locations
- Breast Cancer Research and Treatment (publishedVersion)
- PubMed (publishedVersion)
- YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
- Seoul National University Open Repository (Seoul National University) (submittedVersion)
- Computer Modeling in Engineering & Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- paclitaxel, polymeric micelles, metastatic breast cancer, first-line chemotherapy, second-line chemotherapy, overall response rate, time to progression, peripheral neuropathy, neutropenia, hypersensitivity, drug toxicity
- MeSH terms
- Adult, Aged, Antineoplastic Agents, Phytogenic, Breast Neoplasms, Chemistry, Pharmaceutical, Drug Administration Schedule, Drug Carriers, Drug Compounding, Female, Humans, Infusions, Intravenous, Korea, Micelles, Middle Aged, Neoplasm Metastasis, Polyethylene Glycols, Polymers, Time Factors, Treatment Outcome, Paclitaxel, Kaplan-Meier Estimate
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.